Nasdaq:US$18.12 (-0.52) | HKEX:HK$28.75 (-0.90) | AIM:£2.93 (-0.03)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors